Objective:To investigate the expression of long noncoding RNA (lncRNA) BMPR1B-AS1 in ovarian cancer and its impact on prognosis, so as to evaluate its value as a potential biomarker.Methods:The TCGA, GEPIA, and UALCAN databases were used to retrospectively analyze the expression differences of BMPR1B-AS1 in gynecological tumors, and prognostic analysis was performed in combination with clinical data. The expression level of BMPR1B-AS1 in ovarian cancer tissues and cell lines was verified by real-time fluorescent quantitative reverse transcription polymerase chain reaction (RT-qPCR), and univariate and multivariate Cox regression models were used to analyze its relationship with the prognosis of ovarian cancer.Results:Database analysis showed that the expression of BMPR1B-AS1 in ovarian cancer and endometrial cancer was higher than that in the non-tumor group (all P<0.05), and high expression of BMPR1B-AS1 in ovarian cancer was associated with better prognosis ( P<0.05). Experimental verification showed that the expression of BMPR1B-AS1 in ovarian cancer tissues was significantly higher than that in benign ovarian tissues, and the expression of BMPR1B-AS1 in ovarian cancer cell lines was higher than that in normal human ovarian epithelial cells ( P<0.05). Cox regression analysis indicated that high expression of BMPR1B-AS1 was an independent protective factor for the prognosis of ovarian cancer ( P<0.05). Conclusions:The expression of BMPR1B-AS1 in ovarian cancer and endometrial cancer is higher than that in non-tumor groups, and it is an independent protective factor for good prognosis in ovarian cancer patients. It may serve as a new biomarker, providing new ideas for the diagnosis and treatment of ovarian cancer.

Objective:To investigate the expression of long noncoding RNA (lncRNA) BMPR1B-AS1 in ovarian cancer and its impact on prognosis, so as to evaluate its value as a potential biomarker.Methods:The TCGA, GEPIA, and UALCAN databases were used to retrospectively analyze the expression differences of BMPR1B-AS1 in gynecological tumors, and prognostic analysis was performed in combination with clinical data. The expression level of BMPR1B-AS1 in ovarian cancer tissues and cell lines was verified by real-time fluorescent quantitative reverse transcription polymerase chain reaction (RT-qPCR), and univariate and multivariate Cox regression models were used to analyze its relationship with the prognosis of ovarian cancer.Results:Database analysis showed that the expression of BMPR1B-AS1 in ovarian cancer and endometrial cancer was higher than that in the non-tumor group (all P<0.05), and high expression of BMPR1B-AS1 in ovarian cancer was associated with better prognosis ( P<0.05). Experimental verification showed that the expression of BMPR1B-AS1 in ovarian cancer tissues was significantly higher than that in benign ovarian tissues, and the expression of BMPR1B-AS1 in ovarian cancer cell lines was higher than that in normal human ovarian epithelial cells ( P<0.05). Cox regression analysis indicated that high expression of BMPR1B-AS1 was an independent protective factor for the prognosis of ovarian cancer ( P<0.05). Conclusions:The expression of BMPR1B-AS1 in ovarian cancer and endometrial cancer is higher than that in non-tumor groups, and it is an independent protective factor for good prognosis in ovarian cancer patients. It may serve as a new biomarker, providing new ideas for the diagnosis and treatment of ovarian cancer.